U.S. Consumer Durables Stock News

In January 2026, iRhythm Technologies raised its full-year 2025 revenue guidance to exceed the prior October range and issued new 2026 revenue guidance of about US$870 million to US$880 million, implying roughly 17% to 18% year-over-year growth. The company attributed this upgraded outlook to record fourth-quarter 2025 revenue unit volume, pointing to strong demand for its cardiac monitoring services and devices. Next, we will examine how iRhythm’s upgraded 2025 guidance and double-digit...

Industrial conglomerate Crane Holdings is set to report its quarterly earnings, with analysts expecting earnings per share of US$1.41–US$1.42, following a prior quarter in which the company exceeded revenue, operating income, and EBITDA estimates. Crane currently ranks at the top of its peer group for revenue growth and gross profit margin, underscoring what appears to be relatively strong operational efficiency heading into the latest results. We will now examine how Crane’s peer-leading...

Recent analyst commentary on SiTime (SITM) is centering on its AI focused product positioning, and the appointment of industry veteran Faraj Aalaei to the board adds a fresh technology operator perspective. See our latest analysis for SiTime. SiTime’s recent analyst upgrades and board refresh come after a choppy stretch, with a 1-day share price return of a 5.47% decline and a 30-day share price return of a 9.07% decline, set against a 90-day share price return of 23.88% and a 1-year total...

Coherus Oncology, Inc. recently filed a prospectus supplement allowing it to sell up to US$64.88 million of common stock through an at-the-market offering, shortly after Oppenheimer began covering the company with an Outperform rating based on its oncology pipeline. The focus on the anti-CCR8 antibody tagmokitug and the PD-1 inhibitor Loqtorzi highlights how investors are weighing pipeline potential against ongoing capital needs. We’ll now examine how this combination of fresh equity...

Norfolk Southern has launched its East Edge double-stack intermodal corridor connecting Chicago and New England, replacing an older single-stack route with a faster, higher-capacity line backed by extensive track, bridge, tunnel, and signal upgrades completed with multiple public and private partners. A single 9,000-foot double-stack train on this corridor can theoretically support up to 200,000 loads a year through Ayer, Massachusetts, vastly expanding New England’s primary intermodal hub...

Institutional buying puts ACV Auctions (ACVA) back in focus Iridian Asset Management’s recent purchase of more than 1.1 million ACV Auctions (ACVA) shares, now its largest holding at nearly 9% of assets, has drawn fresh attention to the stock. The investment comes alongside record revenue figures, higher marketplace vehicle volumes, and improving adjusted EBITDA. This has prompted investors to reassess how the company’s current share price lines up with its business performance. See our...

In recent days, CDW has come under pressure after multiple Wall Street firms downgraded or maintained cautious ratings, citing concerns about weaker hardware spending and higher memory costs following revenue and guidance that fell short of expectations despite an earnings per share beat. At the same time, CDW is highlighting its capabilities in enterprise AI and cloud services through Mission Cloud’s work with AWS, underscoring the company’s push into higher-value technology solutions even...

Earlier this year, Monster Energy announced a partnership with Casey’s General Stores to launch a limited-time Ultra Red, White and Blue Razz drink, initially exclusive to Casey’s and CEFCO locations before a wider U.S. rollout. An important aspect of the launch is a joint US$200,000 donation to military-focused nonprofits, aligning the co-branded product with Casey’s community support efforts and visibility among service members through Monster’s Military Channels. We’ll now examine how...

Iridian’s increased stake and recent operating performance Hilton Grand Vacations (HGV) came into focus after Iridian Asset Management lifted its holdings by 190,909 shares in the fourth quarter, an US$8.11 million addition tied to recent operating trends. Iridian now allocates nearly 8% of its reportable assets to Hilton Grand Vacations, following company updates that included a 17% year over year rise in contract sales and reaffirmed full year adjusted EBITDA guidance. See our latest...

Over the past year, Dropbox has seen billings stall while analysts now expect a 1.1% revenue decline over the next 12 months, highlighting pressure on demand for its services. At the same time, the company’s operating margin has been shrinking for two years, pointing to rising concern over cost control and profitability resilience. Next, we’ll examine how stagnating billings and a softer revenue outlook are reshaping Dropbox’s investment narrative for investors. Explore 23 top quantum...

In recent weeks, Oric Pharmaceuticals has drawn increased attention as investors focused on its cancer resistance therapy pipeline, including Phase 1b candidates ORIC-114 and ORIC-944, and its collaborations with Pfizer, Bayer, and Johnson & Johnson. An interesting development is how this combination of early-stage assets and partnerships with large pharmaceutical companies is reshaping perceptions of Oric’s potential role in oncology drug development. Next, we’ll examine how this growing...

In January 2026, Dana Incorporated issued earnings guidance for 2025, projecting annual sales in the range of $7.30 billion to $7.70 billion. This new guidance gives investors a clearer view of Dana’s revenue expectations for the year, sharpening how its future prospects are assessed. Next, we’ll examine how Dana’s specified 2025 sales range shapes its investment narrative and what it could mean for forward expectations. The end of cancer? These 29 emerging AI stocks are developing tech that...

Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑stage trial to test multiple doses. This designation could shorten regulatory timelines and enhance pemvidutide’s profile in the competitive MASH treatment landscape, potentially reshaping Altimmune’s long‑term product mix and risk profile. Next, we’ll examine how pemvidutide’s Breakthrough...

National HealthCare Corporation recently reached a record high level after reporting 22.67% revenue growth over the past year and declaring a US$0.64 quarterly dividend per share, underscoring its focus on returning cash to shareholders. The company’s ‘GREAT’ financial health score, combined with strong recent results and ongoing dividend payments, may be reinforcing investor confidence in its operational resilience. We’ll now examine how National HealthCare’s robust revenue growth and...

In recent months, analysts have become more positive on The RealReal after the company reported past third-quarter results that outpaced forecasts for revenue and adjusted EBITDA. Alongside this, The RealReal’s introduction of its Athena AI system to support authentication, descriptions, and pricing underscores a push toward greater efficiency in its luxury resale operations. Next, we’ll explore how this combination of analyst confidence and Athena-driven operational enhancement shapes The...

In recent days, QuidelOrtho has faced renewed scrutiny over its financial position, with analyses pointing to negative earnings, shrinking margins, a low interest coverage ratio and an Altman Z-Score of 0.2 that places the diagnostics group in the distress zone. Alongside these concerns, the company has highlighted its role in blood-supply resilience and plans to report fourth-quarter and full-year 2025 results on February 11, 2026, underscoring a contrast between operational initiatives and...

Eversource Energy has been reassessing its business mix, pulling back from offshore wind exposure while prioritizing its core regulated transmission and distribution operations amid higher grid upgrade costs and clean‑energy policy uncertainty. This shift, combined with cautious Wall Street views and ongoing regulatory risk, underscores how capital‑intensive infrastructure needs are reshaping the company’s risk profile. Next, we’ll examine how this renewed emphasis on core regulated...

Entegris recently announced that CFO Linda LaGorga will step down in February 2026, with long-time finance executive Mike Sauer assuming the interim CFO role, while also reaffirming its fourth-quarter 2025 outlook and maintaining its regular quarterly dividend. The company emphasized that the CFO transition is amicable and unrelated to any financial or operational disagreements, signaling an effort to preserve continuity and investor confidence during leadership change. We will now examine...

PTC Therapeutics (PTCT) recently issued full year 2026 product revenue guidance of US$700 million to US$800 million, excluding Evrysdi royalties and collaboration revenue. This guidance serves as a key reference point for investors tracking the stock. See our latest analysis for PTC Therapeutics. The 12.18% 3 month share price return and 62.0% 1 year total shareholder return suggest momentum has been building around PTC Therapeutics, with the new 2026 product revenue guidance adding to recent...

Donnelley Financial Solutions recently reported Q3 2025 results that surpassed earnings expectations and outlined plans to increase the share of revenue from software solutions to 60% by 2028, while attracting new investment from the RAM Smid Composite fund. This pivot toward higher-margin software and technology-enabled compliance tools marks a meaningful shift in how the company positions itself within the regulatory and financial reporting ecosystem. We will now examine how Donnelley...

Recent analyst coverage highlighted Perdoceo Education’s past-year revenue growth of 24.23% and earnings-per-share growth of 22.33%, alongside strong profitability, minimal debt, and ample liquidity. Commentary also pointed to the company’s valuation as relatively attractive compared with industry peers, suggesting investors may see a balance of growth potential and financial resilience. Next, we’ll examine how this combination of robust earnings momentum and an apparently attractive...

Royalty Pharma, which acquires rights to portions of biopharmaceutical sales instead of conducting its own research, recently raised its dividend to US$0.235 payable in March 2026 and issued higher guidance ahead of its fourth quarter and full-year 2025 results scheduled for February 11, 2026. This comes after two years of flat sales and a 4.4 percentage point drop in adjusted operating margin over five years, highlighting the tension between investor optimism and questions about how the...

In its latest quarter, Worthington Enterprises reported US$327 million in revenue, surpassing market expectations but missing margin targets due to one-time items following its prior steel business separation. The results marked the company’s eighth consecutive quarter of clean reporting post-separation, a period during which analysts have maintained generally positive views on its prospects. Next, we’ll examine how stronger-than-expected revenue but softer, one-time-affected margins shapes...

10x Genomics (TXG) has moved back into focus after a cluster of research collaborations in autoimmune disease, oncology and AI-driven immuno-oncology, along with preliminary fourth quarter revenue that came in above the company’s own guidance. See our latest analysis for 10x Genomics. Recent collaborations in autoimmune disease and oncology, along with preliminary fourth quarter revenue reported above guidance, have coincided with a sharp rebound in sentiment. The 30 day share price return is...